首页 > 最新文献

Experimental oncology最新文献

英文 中文
IN VIVO STUDY OF POTENTIAL MECHANISMS OF MACROPHAGE REPOLARIZATION ON THE BACKGROUND OF TUMOR GROWTH. 在体内研究肿瘤生长背景下巨噬细胞再极化的潜在机制。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.030
N Fedosova, A Chumak, N Cheremshenko, O Karaman, T Symchych, I Voyeykova

Aim: To study the activity of antitumor immunity effectors and to analyze possible mechanisms of peritoneal Mph M1/M2 repolarization of Balb/c mice under the influence of lectin from B. subtilis IMV B-7724 in the dynamics of the model tumor growth.

Materials and methods: Studies were performed on Balb/c mice; Ehrlich adenocarcinoma (АСЕ) was used as an experimental tumor. Lectin from B. subtilis IMV B-7724 was administered to ACE-bearing mice at a dose of 1 mg/kg of body weight, 10 times. Immunological testing was performed on days 21 and 28 after tumor grafting. The functional activity of peritoneal macrophages (Mph), natural killer (NK) cells, cytotoxic lymphocytes (CTL), and cytokine levels (IFN-γ, IL-4) were studied by the standard methods. mRNA expression levels of transcription factors STAT-1, STAT-6, IRF5, and IRF4 in Mph were evaluated.

Results: The administration of lectin from B. subtilis IMV B-7724 to mice with solid ACE led to the preservation of the initial functional state of peritoneal Mph M1 during the experiment. The bacterial lectin ensured the preservation of the cytotoxic activity of CD8+ T-lymphocytes and a significant (p < 0.05) increase in the NK activity (by 2.7 times compared to the intact animals and by 12.9 times compared to the untreated mice). A strong positive correlation was noted between the levels of the functional activity of Mph and CD8+ T-lymphocytes of animals with tumors and the indices of the antitumor effectiveness of bacterial lectin. The indirect polarization of Mph was evidenced by a strong positive correlation between the level of the NO/Arg ratio (which characterizes the direction of Mph polarization) and the cytotoxic activity of CD8+ T-lymphocytes, NK cells, and the expression of STAT1/STAT6 (the 21st day) and IRF5/IRF4 (the 28th day).

Conclusion: In ACE-bearing mice, repolarization of the peritoneal Mph toward M1 can occur not only due to the direct action of bacterial lectin on the cellular receptors but also with the involvement of other effectors of antitumor immunity (NK cells, T-lymphocytes). The transcription factors of the STAT and IRF signaling pathways are involved in the polarization process.

目的:研究抗肿瘤免疫效应因子的活性,并分析在枯草杆菌凝集素 IMV B-7724 影响下 Balb/c 小鼠腹膜 Mph M1/M2 复极化在模型肿瘤生长动态中的可能机制:研究对象为Balb/c小鼠;艾氏腺癌(АСЕ)被用作实验肿瘤。以每公斤体重 1 毫克的剂量向 ACE 小鼠注射来自枯草杆菌 IMV B-7724 的凝集素,共注射 10 次。在肿瘤移植后的第 21 天和第 28 天进行免疫测试。用标准方法研究了腹腔巨噬细胞(Mph)、自然杀伤细胞(NK)、细胞毒性淋巴细胞(CTL)的功能活性和细胞因子水平(IFN-γ、IL-4),并评估了Mph中转录因子STAT-1、STAT-6、IRF5和IRF4的mRNA表达水平:结果:给患有固体 ACE 的小鼠注射枯草杆菌 IMV B-7724 的凝集素后,腹膜 Mph M1 在实验过程中保持了最初的功能状态。细菌凝集素确保了 CD8+ T 淋巴细胞细胞毒性活性的保持和 NK 活性的显著提高(p < 0.05)(与完整的动物相比提高了 2.7 倍,与未处理的小鼠相比提高了 12.9 倍)。肿瘤动物的 Mph 和 CD8+ T 淋巴细胞的功能活性水平与细菌凝集素的抗肿瘤效果指数之间存在很强的正相关性。Mph的间接极化表现为NO/Arg比值(表征Mph极化的方向)与CD8+ T淋巴细胞、NK细胞的细胞毒性活性以及STAT1/STAT6(第21天)和IRF5/IRF4(第28天)的表达之间存在很强的正相关性:结论:在服用 ACE 的小鼠中,腹膜 Mph 向 M1 的再极化不仅是由于细菌凝集素对细胞受体的直接作用,还与其他抗肿瘤免疫效应因子(NK 细胞、T 淋巴细胞)的参与有关。STAT 和 IRF 信号通路的转录因子参与了极化过程。
{"title":"IN VIVO STUDY OF POTENTIAL MECHANISMS OF MACROPHAGE REPOLARIZATION ON THE BACKGROUND OF TUMOR GROWTH.","authors":"N Fedosova, A Chumak, N Cheremshenko, O Karaman, T Symchych, I Voyeykova","doi":"10.15407/exp-oncology.2024.01.030","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.01.030","url":null,"abstract":"<p><strong>Aim: </strong>To study the activity of antitumor immunity effectors and to analyze possible mechanisms of peritoneal Mph M1/M2 repolarization of Balb/c mice under the influence of lectin from B. subtilis IMV B-7724 in the dynamics of the model tumor growth.</p><p><strong>Materials and methods: </strong>Studies were performed on Balb/c mice; Ehrlich adenocarcinoma (АСЕ) was used as an experimental tumor. Lectin from B. subtilis IMV B-7724 was administered to ACE-bearing mice at a dose of 1 mg/kg of body weight, 10 times. Immunological testing was performed on days 21 and 28 after tumor grafting. The functional activity of peritoneal macrophages (Mph), natural killer (NK) cells, cytotoxic lymphocytes (CTL), and cytokine levels (IFN-γ, IL-4) were studied by the standard methods. mRNA expression levels of transcription factors STAT-1, STAT-6, IRF5, and IRF4 in Mph were evaluated.</p><p><strong>Results: </strong>The administration of lectin from B. subtilis IMV B-7724 to mice with solid ACE led to the preservation of the initial functional state of peritoneal Mph M1 during the experiment. The bacterial lectin ensured the preservation of the cytotoxic activity of CD8+ T-lymphocytes and a significant (p < 0.05) increase in the NK activity (by 2.7 times compared to the intact animals and by 12.9 times compared to the untreated mice). A strong positive correlation was noted between the levels of the functional activity of Mph and CD8+ T-lymphocytes of animals with tumors and the indices of the antitumor effectiveness of bacterial lectin. The indirect polarization of Mph was evidenced by a strong positive correlation between the level of the NO/Arg ratio (which characterizes the direction of Mph polarization) and the cytotoxic activity of CD8+ T-lymphocytes, NK cells, and the expression of STAT1/STAT6 (the 21st day) and IRF5/IRF4 (the 28th day).</p><p><strong>Conclusion: </strong>In ACE-bearing mice, repolarization of the peritoneal Mph toward M1 can occur not only due to the direct action of bacterial lectin on the cellular receptors but also with the involvement of other effectors of antitumor immunity (NK cells, T-lymphocytes). The transcription factors of the STAT and IRF signaling pathways are involved in the polarization process.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"WATCH AND WAIT" STRATEGY IN RECTAL CANCER PATIENTS WITH A COMPLETE CLINICAL RESPONSE AFTER NEOADJUVANT CHEMORADIATION THERAPY: A SINGLE-CENTER EXPERIENCE. 新辅助化放疗后临床反应完全的直肠癌患者的 "观察和等待 "策略:单中心经验。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.053
L Kokaine, M Radzina, M Liepa, A Gerina-Berzina, E Sīviņa, J Nikolajeva, A Gardovskis, J Gardovskis, E Miklaševičs

Background: The non-operative management of rectal adenocarcinoma (RA) after neoadjuvant chemoradiation therapy (nCRT) has gained increasing attention. The "Watch and Wait" ("W&W") strategy allows one to avoid surgery-related reduction in the quality of life due to permanent pelvic organ dysfunction or irreversible stoma. Still, the oncological safety of this strategy is under evaluation.

Aim: To share a single-center experience of the "W&W" strategy.

Materials and methods: The retrospective analysis of 125 patients who received nCRT in 2016-2021 was performed. Patients who met the European Society for Medical Oncology (ESMO, 2017) criteria of clinical complete response (cCR) and received non-operative management were analyzed.

Results: Ten patients (8%) were re-staged after nCRT as cCR and followed the "W&W" strategy. Patients' characteristics: 7 female, 3 male; mean age 67.3 years. Tumor characteristics: pre-treatment N+ was present in 7 cases; G1 adenocarcinoma in a majority of cases; mean tumor distance from the anal verge - 5.85 cm; mean tumor circumference - 71%; mean tumor length - 3.87 cm. The mean follow-up time was 30 months. Local regrowth or/and distant metastases developed in 3 cases. The 2-year disease-free survival was 70%.

Conclusions: Most of the patients following the "W&W" strategy have benefited. However, to reduce the number of relapses, it is necessary to perform a more careful selection of patients.

背景:新辅助化放疗(nCRT)后的直肠腺癌(RA)非手术治疗越来越受到关注。观察和等待"("W&W")策略可以避免因永久性盆腔器官功能障碍或不可逆转的造口而导致的与手术相关的生活质量下降。目的:分享 "观察和等待 "策略的单中心经验:对 2016-2021 年接受 nCRT 的 125 例患者进行回顾性分析。分析了符合欧洲肿瘤内科学会(ESMO,2017年)临床完全反应(cCR)标准并接受非手术治疗的患者:10名患者(8%)在nCRT后重新分期为cCR,并接受了 "W&W "策略。患者特征7名女性,3名男性;平均年龄67.3岁。肿瘤特征:7例治疗前为N+;大多数病例为G1腺癌;肿瘤距离肛门边缘的平均距离为5.85厘米;肿瘤平均周长为71%;肿瘤平均长度为3.87厘米。平均随访时间为 30 个月。3例出现局部再生或/和远处转移。2年无病生存率为70%:结论:大多数采用 "W&W "策略的患者都从中获益。结论:大多数采用 "W&W "策略的患者都从中获益,但为了减少复发,有必要对患者进行更仔细的筛选。
{"title":"\"WATCH AND WAIT\" STRATEGY IN RECTAL CANCER PATIENTS WITH A COMPLETE CLINICAL RESPONSE AFTER NEOADJUVANT CHEMORADIATION THERAPY: A SINGLE-CENTER EXPERIENCE.","authors":"L Kokaine, M Radzina, M Liepa, A Gerina-Berzina, E Sīviņa, J Nikolajeva, A Gardovskis, J Gardovskis, E Miklaševičs","doi":"10.15407/exp-oncology.2024.01.053","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.01.053","url":null,"abstract":"<p><strong>Background: </strong>The non-operative management of rectal adenocarcinoma (RA) after neoadjuvant chemoradiation therapy (nCRT) has gained increasing attention. The \"Watch and Wait\" (\"W&W\") strategy allows one to avoid surgery-related reduction in the quality of life due to permanent pelvic organ dysfunction or irreversible stoma. Still, the oncological safety of this strategy is under evaluation.</p><p><strong>Aim: </strong>To share a single-center experience of the \"W&W\" strategy.</p><p><strong>Materials and methods: </strong>The retrospective analysis of 125 patients who received nCRT in 2016-2021 was performed. Patients who met the European Society for Medical Oncology (ESMO, 2017) criteria of clinical complete response (cCR) and received non-operative management were analyzed.</p><p><strong>Results: </strong>Ten patients (8%) were re-staged after nCRT as cCR and followed the \"W&W\" strategy. Patients' characteristics: 7 female, 3 male; mean age 67.3 years. Tumor characteristics: pre-treatment N+ was present in 7 cases; G1 adenocarcinoma in a majority of cases; mean tumor distance from the anal verge - 5.85 cm; mean tumor circumference - 71%; mean tumor length - 3.87 cm. The mean follow-up time was 30 months. Local regrowth or/and distant metastases developed in 3 cases. The 2-year disease-free survival was 70%.</p><p><strong>Conclusions: </strong>Most of the patients following the \"W&W\" strategy have benefited. However, to reduce the number of relapses, it is necessary to perform a more careful selection of patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VIRGINAL RECURRENT GIGANTOMASTIA (BREAST HYPERTROPHY). A CASE REPORT. 处女膜复发性巨乳症(乳房肥大症)。病例报告。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.073
V Cheshuk, M Anikusko, V Kozina, V Ulishchenko, M Malec

Virginal gigantomastia (VGM) is a benign disease of the breasts without a clearly established etiology. The treatment of VGM remains a problem. The conservative treatment is not effective while surgery is too traumatic. Most specialists recommend subcutaneous mastectomy with immediate implant reconstruction or reduction mammoplasty. The reduction mammoplasty with adjuvant hormone therapy is a variant of treatment of young patients with a risk of recurrence. We present a case of a patient with VGM who was operated in 2014. Reduction mammoplasty was performed. After 9 years, the patient had a relapse and second surgery, resection of the breasts with reduction mammoplasty. Tissues with cysts, fibrosis, hamartomas, and fibroadenomas were dissected. Histopathology revealed extensive fibrosis with hamartomas and fibroadenomas. The immunohistochemical examination of the breast tissue showed a high level (70%) of estrogen and progesterone receptors expression. We prescribed hormone therapy with tamoxifen 10 mg per day. Dynamic monitoring of the treatment result and control of the disease remission was carried out. Breast-conserving surgery performed in such patients can help alleviate the psychological, social, and physical disorders caused by VGM.

处女膜巨乳症(VGM)是一种没有明确病因的乳房良性疾病。畸形巨乳症的治疗仍然是一个难题。保守治疗效果不佳,而手术创伤又太大。大多数专家建议进行皮下乳房切除术,并立即进行假体重建或乳房缩小整形术。缩小乳房成形术配合辅助激素治疗是治疗有复发风险的年轻患者的一种变体。我们介绍了一例于 2014 年接受手术的 VGM 患者。患者接受了乳房缩小成形术。9 年后,患者复发,进行了第二次手术,切除乳房并进行乳房缩小术。切除的组织包括囊肿、纤维化、瘤和纤维腺瘤。组织病理学检查显示,乳房广泛纤维化,并伴有乳房腺瘤和纤维腺瘤。乳腺组织的免疫组化检查显示雌激素和孕激素受体表达水平较高(70%)。我们给她开了激素治疗的处方,他莫昔芬每天 10 毫克。我们对治疗效果进行了动态监测,并控制病情缓解。对此类患者实施保乳手术有助于缓解 VGM 引起的心理、社会和生理障碍。
{"title":"VIRGINAL RECURRENT GIGANTOMASTIA (BREAST HYPERTROPHY). A CASE REPORT.","authors":"V Cheshuk, M Anikusko, V Kozina, V Ulishchenko, M Malec","doi":"10.15407/exp-oncology.2024.01.073","DOIUrl":"10.15407/exp-oncology.2024.01.073","url":null,"abstract":"<p><p>Virginal gigantomastia (VGM) is a benign disease of the breasts without a clearly established etiology. The treatment of VGM remains a problem. The conservative treatment is not effective while surgery is too traumatic. Most specialists recommend subcutaneous mastectomy with immediate implant reconstruction or reduction mammoplasty. The reduction mammoplasty with adjuvant hormone therapy is a variant of treatment of young patients with a risk of recurrence. We present a case of a patient with VGM who was operated in 2014. Reduction mammoplasty was performed. After 9 years, the patient had a relapse and second surgery, resection of the breasts with reduction mammoplasty. Tissues with cysts, fibrosis, hamartomas, and fibroadenomas were dissected. Histopathology revealed extensive fibrosis with hamartomas and fibroadenomas. The immunohistochemical examination of the breast tissue showed a high level (70%) of estrogen and progesterone receptors expression. We prescribed hormone therapy with tamoxifen 10 mg per day. Dynamic monitoring of the treatment result and control of the disease remission was carried out. Breast-conserving surgery performed in such patients can help alleviate the psychological, social, and physical disorders caused by VGM.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PSAMMOMA BODIES IN LYMPH NODES OF THE NECK: POSSIBLE PRECURSOR OF LOCOREGIONAL METASTASES OF PAPILLARY THYROID CARCINOMA. 颈部淋巴结中的脓肿体:甲状腺乳头状癌局部转移的可能前兆。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.061
A Dinets, M Gorobeiko, A Lovin, V Dibrova, V Hoperia

Background: Papillary thyroid carcinoma (PTC) is the most common type of well-differentiated thyroid cancer accounting for up to 80% of all thyroid neoplasms. Metastases to the regional lymph nodes (RLN) of the neck are a feature of its biological aggressiveness. The presence of psammoma bodies may be considered a pathomorphological feature of PTC in addition to the papillary structure of tumor and specific nuclear changes. The aim of the study was to evaluate a clinical value of psammoma bodies in the RLN of PTC patients.

Materials and methods: 91 patients with PTC who were surgically treated at the Verum Expert Clinic were enrolled in the study. The clinical and pathomorphological data were retrieved from the archival medical records.

Results: According to the results of the clinico-morphological analysis, 51 patients (56%) with PTC had metastases in the RLN of the neck, and 40 (44%) patients had no metastases. Among 51 patients with metastases in the RLN, in 4 patients psammoma bodies in the RLN and tumor tissue were identified. In 3 of these 4 patients, the size of the primary PTC tumor was less than 10 mm, but an aggressive cancer course such as significant number of metastases in the RLN or multifocal growth was found in all these cases.

Conclusions: The presence of psammoma bodies in RLN and primary PTC tumor could be suggested as a predictor of metastasis to lymph nodes. The detection of point echogenic foci in the lymph nodes by ultrasound at the preoperative stage is a sign of psammoma bodies. This finding can be useful for improving the efficacy in selection of surgical treatment tactics for the optimal neck dissection by planning neck dissection in the presence of such point echogenic foci at the preoperative stage and performing regular check-ups of the patients.

背景:甲状腺乳头状癌(PTC甲状腺乳头状癌(PTC)是分化良好的甲状腺癌中最常见的类型,占所有甲状腺肿瘤的80%。颈部区域淋巴结(RLN)转移是其生物学侵袭性的一个特征。除了肿瘤的乳头状结构和特异性核变化外,出现乳头状瘤体可被视为PTC的病理形态学特征。研究的目的是评估 PTC 患者 RLN 中的脓肿体的临床价值。临床和病理形态学数据均来自档案病历:临床形态学分析结果显示,51 名 PTC 患者(56%)的颈部 RLN 有转移,40 名患者(44%)没有转移。在 51 名有颈部淋巴结转移的患者中,有 4 名患者的颈部淋巴结和肿瘤组织中发现了脓肿体。在这4名患者中,有3名患者的原发性PTC肿瘤大小小于10毫米,但在所有这些病例中都发现了侵袭性癌症病程,如在RLN中发现大量转移灶或多灶生长:结论:RLN和原发性PTC肿瘤中出现的脓肿体可作为淋巴结转移的预测指标。在术前阶段通过超声检查在淋巴结中发现点状回声灶是炎性瘤体的一个标志。这一发现有助于提高手术治疗策略的选择效率,在术前阶段出现此类点状回声灶时计划进行颈部清扫,并对患者进行定期检查,以获得最佳颈部清扫效果。
{"title":"PSAMMOMA BODIES IN LYMPH NODES OF THE NECK: POSSIBLE PRECURSOR OF LOCOREGIONAL METASTASES OF PAPILLARY THYROID CARCINOMA.","authors":"A Dinets, M Gorobeiko, A Lovin, V Dibrova, V Hoperia","doi":"10.15407/exp-oncology.2024.01.061","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.01.061","url":null,"abstract":"<p><strong>Background: </strong>Papillary thyroid carcinoma (PTC) is the most common type of well-differentiated thyroid cancer accounting for up to 80% of all thyroid neoplasms. Metastases to the regional lymph nodes (RLN) of the neck are a feature of its biological aggressiveness. The presence of psammoma bodies may be considered a pathomorphological feature of PTC in addition to the papillary structure of tumor and specific nuclear changes. The aim of the study was to evaluate a clinical value of psammoma bodies in the RLN of PTC patients.</p><p><strong>Materials and methods: </strong>91 patients with PTC who were surgically treated at the Verum Expert Clinic were enrolled in the study. The clinical and pathomorphological data were retrieved from the archival medical records.</p><p><strong>Results: </strong>According to the results of the clinico-morphological analysis, 51 patients (56%) with PTC had metastases in the RLN of the neck, and 40 (44%) patients had no metastases. Among 51 patients with metastases in the RLN, in 4 patients psammoma bodies in the RLN and tumor tissue were identified. In 3 of these 4 patients, the size of the primary PTC tumor was less than 10 mm, but an aggressive cancer course such as significant number of metastases in the RLN or multifocal growth was found in all these cases.</p><p><strong>Conclusions: </strong>The presence of psammoma bodies in RLN and primary PTC tumor could be suggested as a predictor of metastasis to lymph nodes. The detection of point echogenic foci in the lymph nodes by ultrasound at the preoperative stage is a sign of psammoma bodies. This finding can be useful for improving the efficacy in selection of surgical treatment tactics for the optimal neck dissection by planning neck dissection in the presence of such point echogenic foci at the preoperative stage and performing regular check-ups of the patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER. 乳腺癌患者肿瘤组织中 spp1 和 sparc 基因的表达。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.013
V Chekhun, A Pavlova, T Zadvornyi, T Borikun, L Naleskina, O Mushii, V Bazas, N Lukianova

Background: Breast cancer (BCa) is one of the most common oncological diseases in women in Ukraine and worldwide, which determines the need to search for new diagnostic and prognostic markers. In this aspect, the study of multicellular proteins, in particular osteopontin (OPN) and osteonectin (ON), in BCа tissue is relevant. The aim of the work was to investigate the expression of SPP1 and SPARC at the mRNA and protein levels in BCa tissue and to assess their relationship with the main clinicopathological BCa characteristics and the survival rates of patients.

Materials and methods: The work was based on the analysis of the results of the examination and treatment of 60 patients with stage II-III BCa and 15 patients with breast fibroadenomas. SPP1 and SPARC mRNA levels were determined by real-time PCR. The study of the expression of protein products of the SPP1 and SPARC genes was carried out by the immunohistochemical method.

Results: We have established that the BCa tissue was characterized by 3.5 (p < 0.05) and 7.4 (p < 0.05) lower levels of SPP1 and SPARC mRNA, respectively, compared to the tissue of benign neoplasms, while OPN and ON expression levels were 1.6 (p < 0.05) and 5.6 (p < 0.05) times higher, respectively, compared to fibroadenoma tissue. The analysis of the relationship between the expression of SPP1 and SPARC at the protein and mRNA levels in BCa tissue and the main clinicopathological BCa characteristics revealed its dependence on the presence of metastases in regional lymph nodes, differentiation grade, and the molecular BCa subtype. Also, high expression levels of SPP1 and OPN were associated with worse patient survival rates.

Conclusion: The obtained results indicate the perspective of using SPP1 and SPARC expression indices in BCa tissue to assess the aggressiveness of the cancer course and optimize the tactics of treating patients.

背景乳腺癌(BCa)是乌克兰乃至全世界妇女最常见的肿瘤疾病之一,因此需要寻找新的诊断和预后标志物。在这方面,研究 BCa 组织中的多细胞蛋白,特别是骨连接蛋白(OPN)和骨连接蛋白(ON)具有重要意义。该研究旨在调查 BCa 组织中 SPP1 和 SPARC 在 mRNA 和蛋白水平的表达情况,并评估它们与 BCa 主要临床病理特征和患者生存率之间的关系:该研究基于对60例II-III期BCa患者和15例乳腺纤维腺瘤患者的检查和治疗结果的分析。通过实时 PCR 测定 SPP1 和 SPARC mRNA 水平。免疫组化法研究了 SPP1 和 SPARC 基因蛋白产物的表达:结果:我们发现,与良性肿瘤组织相比,BCa组织的SPP1和SPARC mRNA水平分别低3.5(P<0.05)和7.4(P<0.05)倍,而与纤维腺瘤组织相比,OPN和ON的表达水平分别高1.6(P<0.05)和5.6(P<0.05)倍。对BCa组织中SPP1和SPARC在蛋白和mRNA水平的表达与BCa主要临床病理特征之间关系的分析表明,SPP1和SPARC的表达与区域淋巴结有无转移、分化分级和分子BCa亚型有关。此外,SPP1和OPN的高表达水平与较差的患者生存率有关:结论:研究结果表明,可以利用 BCa 组织中 SPP1 和 SPARC 的表达指数来评估癌症病程的侵袭性,并优化患者的治疗策略。
{"title":"EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER.","authors":"V Chekhun, A Pavlova, T Zadvornyi, T Borikun, L Naleskina, O Mushii, V Bazas, N Lukianova","doi":"10.15407/exp-oncology.2024.01.013","DOIUrl":"10.15407/exp-oncology.2024.01.013","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BCa) is one of the most common oncological diseases in women in Ukraine and worldwide, which determines the need to search for new diagnostic and prognostic markers. In this aspect, the study of multicellular proteins, in particular osteopontin (OPN) and osteonectin (ON), in BCа tissue is relevant. The aim of the work was to investigate the expression of SPP1 and SPARC at the mRNA and protein levels in BCa tissue and to assess their relationship with the main clinicopathological BCa characteristics and the survival rates of patients.</p><p><strong>Materials and methods: </strong>The work was based on the analysis of the results of the examination and treatment of 60 patients with stage II-III BCa and 15 patients with breast fibroadenomas. SPP1 and SPARC mRNA levels were determined by real-time PCR. The study of the expression of protein products of the SPP1 and SPARC genes was carried out by the immunohistochemical method.</p><p><strong>Results: </strong>We have established that the BCa tissue was characterized by 3.5 (p < 0.05) and 7.4 (p < 0.05) lower levels of SPP1 and SPARC mRNA, respectively, compared to the tissue of benign neoplasms, while OPN and ON expression levels were 1.6 (p < 0.05) and 5.6 (p < 0.05) times higher, respectively, compared to fibroadenoma tissue. The analysis of the relationship between the expression of SPP1 and SPARC at the protein and mRNA levels in BCa tissue and the main clinicopathological BCa characteristics revealed its dependence on the presence of metastases in regional lymph nodes, differentiation grade, and the molecular BCa subtype. Also, high expression levels of SPP1 and OPN were associated with worse patient survival rates.</p><p><strong>Conclusion: </strong>The obtained results indicate the perspective of using SPP1 and SPARC expression indices in BCa tissue to assess the aggressiveness of the cancer course and optimize the tactics of treating patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ANTICANCER IMMUNOGENIC POTENTIAL OF ONCOLYTIC PEPTIDES: RECENT ADVANCES AND NEW PROSPECTS. 溶瘤肽的抗癌免疫潜力:最新进展和新前景。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.003
N Khranovska, O Skachkova, O Gorbach, I Semchuk, Yu Shvets, I Komarov

Oncolytic peptides are derived from natural host defense peptides/antimicrobial peptides produced in a wide variety of life forms. Over the past two decades, they have attracted much attention in both basic research and clinical applications. Oncolytic peptides were expected to act primarily on tumor cells and also trigger the immunogenic cell death. Their ability in the tumor microenvironment remodeling and potentiating the anticancer immunity has long been ignored. Despite the promising results, clinical application of oncolytic peptides is still hindered by their unsatisfactory bioactivity and toxicity to normal cells. To ensure safer therapy, various approaches are being developed. The idea of the Ukrainian research group was to equip peptide molecules with a "molecular photoswitch" - a diarylethene fragment capable of photoisomerization, allowing for the localized photoactivation of peptides within tumors reducing side effects. Such oncolytic peptides that may induce the membrane lysis-mediated cancer cell death and subsequent anticancer immune responses in combination with the low toxicity to normal cells have provided a new paradigm for cancer therapy. This review gives an overview of the broad effects and perspectives of oncolytic peptides in anticancer immunity highlighting the potential issues related to the use of oncolytic peptides in cancer immunotherapy. We summarize the current status of research on peptide-based tumor immunotherapy in combination with other therapies including immune checkpoint inhibitors, chemotherapy, and targeted therapy.

溶瘤肽来源于多种生命形式产生的天然宿主防御肽/抗菌肽。在过去二十年里,它们在基础研究和临床应用方面都引起了广泛关注。人们认为溶瘤肽主要作用于肿瘤细胞,同时也会引发免疫性细胞死亡。长期以来,它们在重塑肿瘤微环境和增强抗癌免疫力方面的能力一直被忽视。尽管溶瘤肽取得了令人鼓舞的成果,但由于其生物活性和对正常细胞的毒性不尽人意,其临床应用仍然受到阻碍。为了确保更安全的治疗,目前正在开发各种方法。乌克兰研究小组的想法是在多肽分子上安装 "分子光开关"--一种能发生光异构化的二元乙烯片段,从而在肿瘤内局部光激活多肽,减少副作用。这种溶瘤肽可诱导膜裂解介导的癌细胞死亡,随后产生抗癌免疫反应,同时对正常细胞毒性低,为癌症治疗提供了新的范例。本综述概述了溶瘤肽在抗癌免疫中的广泛作用和前景,强调了在癌症免疫疗法中使用溶瘤肽的潜在问题。我们总结了基于肽的肿瘤免疫疗法与其他疗法(包括免疫检查点抑制剂、化疗和靶向疗法)相结合的研究现状。
{"title":"ANTICANCER IMMUNOGENIC POTENTIAL OF ONCOLYTIC PEPTIDES: RECENT ADVANCES AND NEW PROSPECTS.","authors":"N Khranovska, O Skachkova, O Gorbach, I Semchuk, Yu Shvets, I Komarov","doi":"10.15407/exp-oncology.2024.01.003","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.01.003","url":null,"abstract":"<p><p>Oncolytic peptides are derived from natural host defense peptides/antimicrobial peptides produced in a wide variety of life forms. Over the past two decades, they have attracted much attention in both basic research and clinical applications. Oncolytic peptides were expected to act primarily on tumor cells and also trigger the immunogenic cell death. Their ability in the tumor microenvironment remodeling and potentiating the anticancer immunity has long been ignored. Despite the promising results, clinical application of oncolytic peptides is still hindered by their unsatisfactory bioactivity and toxicity to normal cells. To ensure safer therapy, various approaches are being developed. The idea of the Ukrainian research group was to equip peptide molecules with a \"molecular photoswitch\" - a diarylethene fragment capable of photoisomerization, allowing for the localized photoactivation of peptides within tumors reducing side effects. Such oncolytic peptides that may induce the membrane lysis-mediated cancer cell death and subsequent anticancer immune responses in combination with the low toxicity to normal cells have provided a new paradigm for cancer therapy. This review gives an overview of the broad effects and perspectives of oncolytic peptides in anticancer immunity highlighting the potential issues related to the use of oncolytic peptides in cancer immunotherapy. We summarize the current status of research on peptide-based tumor immunotherapy in combination with other therapies including immune checkpoint inhibitors, chemotherapy, and targeted therapy.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CORRECTION OF PATHOLOGICAL CHANGES IN SALIVARY GLANDS OF ANIMALS WITH PACLITAXEL-INDUCED NEUROPATHY. 纠正紫杉醇诱发神经病变动物唾液腺的病理变化。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.038
K Tykhonovych, T Kryvoruchko, N Nikitina, S Berehovyi, K Neporada

Background: Paclitaxel is a highly effective chemotherapeutic agent used to treat breast, ovarian, and other cancers. At the same time, paclitaxel causes peripheral neuropathy as a side effect in 45%-70% of patients.

Aim: The aim of the study was to investigate the effect of paclitaxel-induced peripheral neuropathy on the development of pathological changes in the salivary glands of animals and to explore the possibility of correction of the identified changes with vitamin B/ATP complex.

Materials and methods: To simulate toxic neuropathy, animals were injected i/p with paclitaxel 2 mg/kg for 4 days. In order to correct the identified changes, rats were injected i/m with vitamin B/ATP complex (1 mg/ kg) for 9 days. In the homogenate of the submandibular salivary glands, α-amylase activity, total proteolytic activity, total antitryptic activity, the content of medium mass molecules, thiobarbituric acid reactive substances (TBARS), oxidatively modified proteins, and catalase activity were determined.

Results: A significant increase in the content of oxidatively modified proteins, medium mass molecules, and the content of TBARS and significant decrease in the activity of catalase and amylase were determined in the salivary glands of animals with toxic neuropathy compared to these parameters in intact animals. Administration of vitamin B/ATP complex for 9 days against the background of paclitaxel-induced neuropathy led to normalization of antitryptic activity and amylase activity, a significant decrease in the content of oxidatively modified proteins, medium mass molecules, and TBARS along with a significant increase in catalase activity in the salivary glands of animals compared to the untreated rats with neuropathy.

Conclusion: Paclitaxel-induced neuropathy caused the development of pathological changes in the salivary glands of rats, which was evidenced by a carbonyl- oxidative stress and impaired protein synthetic function. The correction with vitamin B/ATP complex restored the protein-synthetic function and the proteinase-inhibitor balance, suppressed the oxidative stress and normalized free radical processes in the salivary glands of rats.

背景:紫杉醇是一种用于治疗乳腺癌、卵巢癌和其他癌症的高效化疗药物。目的:本研究旨在探讨紫杉醇诱导的周围神经病变对动物唾液腺病理变化发展的影响,并探讨用维生素 B/ATP 复合物纠正已发现变化的可能性:为了模拟中毒性神经病变,动物体内/体外注射紫杉醇2毫克/千克,连续4天。为了纠正已发现的变化,给大鼠注射维生素 B/ATP 复合物(1 毫克/千克),连续 9 天。测定了颌下腺匀浆中的α-淀粉酶活性、总蛋白水解活性、总抗胰蛋白酶活性、中等质量分子含量、硫代巴比妥酸活性物质(TBARS)、氧化修饰蛋白质和过氧化氢酶活性:结果:与完整动物的这些参数相比,中毒性神经病变动物唾液腺中氧化修饰的蛋白质、中质分子和 TBARS 的含量明显增加,过氧化氢酶和淀粉酶的活性明显下降。在紫杉醇诱导的神经病变背景下,连续 9 天服用维生素 B/ATP 复合物可使抗胰蛋白酶活性和淀粉酶活性恢复正常,氧化修饰的蛋白质、中等质量分子和 TBARS 的含量显著降低,与未治疗的神经病变大鼠相比,动物唾液腺中过氧化氢酶的活性显著提高:结论:紫杉醇诱导的神经病变导致大鼠唾液腺发生病理变化,表现为羰基氧化应激和蛋白质合成功能受损。维生素 B/ATP 复合物可恢复大鼠唾液腺的蛋白质合成功能和蛋白酶抑制剂平衡,抑制氧化应激,使自由基过程恢复正常。
{"title":"CORRECTION OF PATHOLOGICAL CHANGES IN SALIVARY GLANDS OF ANIMALS WITH PACLITAXEL-INDUCED NEUROPATHY.","authors":"K Tykhonovych, T Kryvoruchko, N Nikitina, S Berehovyi, K Neporada","doi":"10.15407/exp-oncology.2024.01.038","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.01.038","url":null,"abstract":"<p><strong>Background: </strong>Paclitaxel is a highly effective chemotherapeutic agent used to treat breast, ovarian, and other cancers. At the same time, paclitaxel causes peripheral neuropathy as a side effect in 45%-70% of patients.</p><p><strong>Aim: </strong>The aim of the study was to investigate the effect of paclitaxel-induced peripheral neuropathy on the development of pathological changes in the salivary glands of animals and to explore the possibility of correction of the identified changes with vitamin B/ATP complex.</p><p><strong>Materials and methods: </strong>To simulate toxic neuropathy, animals were injected i/p with paclitaxel 2 mg/kg for 4 days. In order to correct the identified changes, rats were injected i/m with vitamin B/ATP complex (1 mg/ kg) for 9 days. In the homogenate of the submandibular salivary glands, α-amylase activity, total proteolytic activity, total antitryptic activity, the content of medium mass molecules, thiobarbituric acid reactive substances (TBARS), oxidatively modified proteins, and catalase activity were determined.</p><p><strong>Results: </strong>A significant increase in the content of oxidatively modified proteins, medium mass molecules, and the content of TBARS and significant decrease in the activity of catalase and amylase were determined in the salivary glands of animals with toxic neuropathy compared to these parameters in intact animals. Administration of vitamin B/ATP complex for 9 days against the background of paclitaxel-induced neuropathy led to normalization of antitryptic activity and amylase activity, a significant decrease in the content of oxidatively modified proteins, medium mass molecules, and TBARS along with a significant increase in catalase activity in the salivary glands of animals compared to the untreated rats with neuropathy.</p><p><strong>Conclusion: </strong>Paclitaxel-induced neuropathy caused the development of pathological changes in the salivary glands of rats, which was evidenced by a carbonyl- oxidative stress and impaired protein synthetic function. The correction with vitamin B/ATP complex restored the protein-synthetic function and the proteinase-inhibitor balance, suppressed the oxidative stress and normalized free radical processes in the salivary glands of rats.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LIUBOV HEORHIIVNA BUCHYNSKA. liubov heorhiivna buchynska.
Pub Date : 2024-05-31

Director of the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Doctor of Biological Sciences Professor Liubov Heorhiivna Buchynska celebrates her 75th anniversary   Liubov Heorhiivna Buchynska graduated from the Biological Department of the Taras Shevchenko State University in 1977 and has been working at the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine since 1977. In 1996, she became the Scientific Secretary of the Institute, in 2001 - the Deputy Director, and in 2021 - Director of the Institute. In 1989, L. Buchynska  received her PhD degree and in 2012,  she defended her doctoral thesis "Endometrioid cancer: taxonomy of genetic alterations of cancer cells and their role in determining malignancy potential" and received her doctoral degree in specialty "oncology". Since 2003, she has headed the Laboratory of Oncogenetics (nowadays - the Department of Genetics of Cancer and Oncohematology). In 2020, L. Buchynska was given the title of Professor in Biology.  Prof. L. Buchynska is a well-known Ukrainian scientist in the field of oncogenetics and cytomorphology. Her long-term studies are characterized by a multidisciplinary approach to solving the problems of cancer biology and genetics. The innovation component occupies an important place in the fundamental studies by Prof. L. Buchynska aimed at implementing technologies for early and differential diagnosis of the precancerous and cancerous processes and assessing  the course of the disease in patients with malignancies of the organs of the female reproductive system. Prof. L. Buchynska has authored more than 250 scientific papers and 7 patents of Ukraine. She is a co-author of three monographs. She pays special attention to research-and-organizational and educational activities and training of young researchers. She has supervised five PhD theses. For the last 10 years, she has been collaborating with the Bogomolets National Medical University lecturing biology.  Prof. L. Buchynska is the Deputy Editor-in-Chief of the "Experimental Oncology" and "Oncology" journals, a member of the Scientific Council on the Problems of Malignant Neoplasms, a member of the Board of the National Association of Ukrainian Oncologists and the Non-governmental Organization "Ukrainian Society for Cancer Research". Prof. L. Buchynska was awarded the Bogomolets Prize of the National Academy of Sciences of Ukraine and a Certificate of Merit of the National Academy of Sciences of Ukraine. She was decorated with the Medal of Honor of the National Academy of Sciences of Ukraine "For Scientific Achievements". Holding the helm of the Institute in difficult times for our country, Liubov Heorhiivna is doing her best for a noble goal - fighting cancer. The administration and staff of the Institute have a great pleasure to congratulate Liubov Heorhiivna on her 75th annive

乌克兰国家科学院 R.E. Kavetsky 实验病理学、肿瘤学和放射生物学研究所所长、生物科学博士 Liubov Heorhiivna Buchynska 教授庆祝从教 75 周年 Liubov Heorhiivna Buchynska 1977 年毕业于塔拉斯-舍甫琴科国立大学生物系,自 1977 年起一直在乌克兰国家科学院 R.E. Kavetsky 实验病理学、肿瘤学和放射生物学研究所工作。1996 年,她成为研究所的科学秘书,2001 年成为副所长,2021 年成为研究所所长。1989 年,L. Buchynska 获得博士学位。2012 年,她通过了博士论文答辩 "子宫内膜癌:癌细胞基因改变的分类及其在决定恶性潜能中的作用",并获得 "肿瘤学 "专业博士学位。自 2003 年以来,她一直担任肿瘤遗传学实验室(现为癌症遗传学和肿瘤血液学系)负责人。2020 年,L. Buchynska 被授予生物学教授头衔。 L. Buchynska 教授是乌克兰肿瘤遗传学和细胞形态学领域的著名科学家。她长期研究的特点是采用多学科方法解决癌症生物学和遗传学问题。在 L. Buchynska 教授的基础研究中,创新部分占据了重要位置,其目的是采用技术对癌前病变和癌症过程进行早期诊断和鉴别诊断,并对女性生殖系统器官恶性肿瘤患者的病程进行评估。L. Buchynska 教授撰写了 250 多篇科学论文和 7 项乌克兰专利。她还是三部专著的合著者。她特别关注研究、组织和教育活动以及年轻研究人员的培训。她指导过五篇博士论文。在过去 10 年中,她一直与 Bogomolets 国立医科大学合作讲授生物学课程。 L. Buchynska 教授是《实验肿瘤学》(Experimental Oncology)和《肿瘤学》(Oncology)杂志的副主编、恶性肿瘤问题科学委员会成员、乌克兰全国肿瘤学家协会和非政府组织 "乌克兰癌症研究学会 "的理事会成员。L. Buchynska 教授曾获得乌克兰国家科学院 Bogomolets 奖和乌克兰国家科学院荣誉证书。她还被授予乌克兰国家科学院 "科学成就 "荣誉奖章。Liubov Heorhiivna 在国家困难时期担任研究所所长,为实现抗癌这一崇高目标竭尽全力。研究所的领导和工作人员非常高兴地祝贺柳博芙-赫奥里耶芙娜 75 周年,并祝愿她身体健康、灵感迸发、取得新的科研成果。 乌克兰国家科学院 R.E. Kavetsky 实验病理学、肿瘤学和放射生物学研究所管理部门和工作人员 《实验肿瘤学》编辑委员会。
{"title":"LIUBOV HEORHIIVNA BUCHYNSKA.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Director of the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Doctor of Biological Sciences Professor Liubov Heorhiivna Buchynska celebrates her 75th anniversary   Liubov Heorhiivna Buchynska graduated from the Biological Department of the Taras Shevchenko State University in 1977 and has been working at the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine since 1977. In 1996, she became the Scientific Secretary of the Institute, in 2001 - the Deputy Director, and in 2021 - Director of the Institute. In 1989, L. Buchynska  received her PhD degree and in 2012,  she defended her doctoral thesis \"Endometrioid cancer: taxonomy of genetic alterations of cancer cells and their role in determining malignancy potential\" and received her doctoral degree in specialty \"oncology\". Since 2003, she has headed the Laboratory of Oncogenetics (nowadays - the Department of Genetics of Cancer and Oncohematology). In 2020, L. Buchynska was given the title of Professor in Biology.  Prof. L. Buchynska is a well-known Ukrainian scientist in the field of oncogenetics and cytomorphology. Her long-term studies are characterized by a multidisciplinary approach to solving the problems of cancer biology and genetics. The innovation component occupies an important place in the fundamental studies by Prof. L. Buchynska aimed at implementing technologies for early and differential diagnosis of the precancerous and cancerous processes and assessing  the course of the disease in patients with malignancies of the organs of the female reproductive system. Prof. L. Buchynska has authored more than 250 scientific papers and 7 patents of Ukraine. She is a co-author of three monographs. She pays special attention to research-and-organizational and educational activities and training of young researchers. She has supervised five PhD theses. For the last 10 years, she has been collaborating with the Bogomolets National Medical University lecturing biology.  Prof. L. Buchynska is the Deputy Editor-in-Chief of the \"Experimental Oncology\" and \"Oncology\" journals, a member of the Scientific Council on the Problems of Malignant Neoplasms, a member of the Board of the National Association of Ukrainian Oncologists and the Non-governmental Organization \"Ukrainian Society for Cancer Research\". Prof. L. Buchynska was awarded the Bogomolets Prize of the National Academy of Sciences of Ukraine and a Certificate of Merit of the National Academy of Sciences of Ukraine. She was decorated with the Medal of Honor of the National Academy of Sciences of Ukraine \"For Scientific Achievements\". Holding the helm of the Institute in difficult times for our country, Liubov Heorhiivna is doing her best for a noble goal - fighting cancer. The administration and staff of the Institute have a great pleasure to congratulate Liubov Heorhiivna on her 75th annive","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HOLOTHURIA SCABRA METHANOL EXTRACT INHIBITS CANCER GROWTH THROUGH TGF-β/PI3K/PTEN SIGNALING PATHWAY IN BREAST CANCER MICE MODEL. HOLOTHURIA SCABRA METHANOL EXTRACT INHIBITS CANCER GROWTHING THROUGH TGF-β/PI3K/PTEN SIGNALING PATHWAY IN BREAST CANCER MICE MODEL.
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.022
Hana Ratnawati, Teresa Liliana Wargasetia, Larissa Larissa, Liana Alvitri, Keane Bryant

Background: Molecules and cytokines can be targeted in cancer therapy. Transforming growth factor-beta (TGF-β) is a cytokine that acts on protein kinase receptors in the plasma membrane. The signaling pathway of TGF-β can trigger the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, a signal transduction pathway important in cancer growth and development. However, this PI3K/AKT cascade can be inhibited by phosphatase and tensin homolog (PTEN) tumor suppressor genes.

Aim: To determine the inhibitory effect of Holothuria scabra methanol extract (HSE) on breast cancer growth through the TGF-β/PI3K pathways and PTEN tumor suppressor gene on a breast cancer (BC) mice model.

Materials and methods: Female C57BL6 mice were subcutaneously injected with carcinogen DMBA 1 mg/kg body weight (BW) and fed a high-fat diet (HFD). Mice were randomly divided into five groups (n = 6): negative control (NC) administered with a standard diet, positive control (PC) administered with DMBA and HFD, and three treatment groups (T1, T2, and T3) treated with HSE doses of 0.33, 0.66, and 0.99 g/kg BW for 12 weeks. TGF-β concentration in the blood serum of mice was assessed by ELISA and the PIK3CA and PTEN gene expression by qRT-PCR.

Results: The treatment with HSE resulted in a significant decrease in TGF-β concentrations in the blood sera of treatment groups T1 (35.31 ± 17.33), T2 (43.31 ± 17.42), and T3 (48.67 ± 20.94) pg/mL compared to the PC group (162.09 ± 11.60) pg/mL (p < 0.001). However, only HSE at a dose of 0.99 g/kg BW decreased the PIK3CA gene expression (p = 0.026), and at a dose of 0.66 g/kg BW increased the PTEN expression up to 4.93-fold.

Conclusion: HSE is capable of inhibiting the TGF-β/PIK3CA pathway and increasing the PTEN gene expression.

背景:分子和细胞因子可作为癌症治疗的靶点。转化生长因子-β(TGF-β)是一种作用于质膜蛋白激酶受体的细胞因子。TGF-β 的信号通路可触发磷脂酰肌醇-4,5-二磷酸 3-激酶(PI3K)通路,这是一种对癌症生长和发展非常重要的信号转导通路。目的:通过TGF-β/PI3K通路和PTEN肿瘤抑制基因,确定Holothuria scabra甲醇提取物(HSE)对乳腺癌(BC)小鼠模型中乳腺癌生长的抑制作用:雌性 C57BL6 小鼠皮下注射致癌物质 DMBA 1 毫克/千克体重(BW),并喂食高脂饮食(HFD)。小鼠被随机分为五组(n = 6):使用标准饮食的阴性对照组(NC)、使用 DMBA 和 HFD 的阳性对照组(PC)以及使用 0.33、0.66 和 0.99 g/kg BW 剂量的 HSE 治疗 12 周的三个治疗组(T1、T2 和 T3)。小鼠血清中的 TGF-β 浓度通过 ELISA 进行评估,PIK3CA 和 PTEN 基因表达通过 qRT-PCR 进行评估:结果:与 PC 组(162.09 ± 11.60)pg/mL 相比,HSE 治疗组 T1(35.31 ± 17.33)、T2(43.31 ± 17.42)和 T3(48.67 ± 20.94)pg/mL 的血清中 TGF-β 浓度显著下降(p < 0.001)。然而,只有剂量为 0.99 g/kg BW 的 HSE 能降低 PIK3CA 基因的表达(p = 0.026),而剂量为 0.66 g/kg BW 的 HSE 能增加 PTEN 的表达达 4.93 倍:结论:HSE 能够抑制 TGF-β/PIK3CA 通路并增加 PTEN 基因的表达。
{"title":"HOLOTHURIA SCABRA METHANOL EXTRACT INHIBITS CANCER GROWTH THROUGH TGF-β/PI3K/PTEN SIGNALING PATHWAY IN BREAST CANCER MICE MODEL.","authors":"Hana Ratnawati, Teresa Liliana Wargasetia, Larissa Larissa, Liana Alvitri, Keane Bryant","doi":"10.15407/exp-oncology.2024.01.022","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.01.022","url":null,"abstract":"<p><strong>Background: </strong>Molecules and cytokines can be targeted in cancer therapy. Transforming growth factor-beta (TGF-β) is a cytokine that acts on protein kinase receptors in the plasma membrane. The signaling pathway of TGF-β can trigger the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, a signal transduction pathway important in cancer growth and development. However, this PI3K/AKT cascade can be inhibited by phosphatase and tensin homolog (PTEN) tumor suppressor genes.</p><p><strong>Aim: </strong>To determine the inhibitory effect of Holothuria scabra methanol extract (HSE) on breast cancer growth through the TGF-β/PI3K pathways and PTEN tumor suppressor gene on a breast cancer (BC) mice model.</p><p><strong>Materials and methods: </strong>Female C57BL6 mice were subcutaneously injected with carcinogen DMBA 1 mg/kg body weight (BW) and fed a high-fat diet (HFD). Mice were randomly divided into five groups (n = 6): negative control (NC) administered with a standard diet, positive control (PC) administered with DMBA and HFD, and three treatment groups (T1, T2, and T3) treated with HSE doses of 0.33, 0.66, and 0.99 g/kg BW for 12 weeks. TGF-β concentration in the blood serum of mice was assessed by ELISA and the PIK3CA and PTEN gene expression by qRT-PCR.</p><p><strong>Results: </strong>The treatment with HSE resulted in a significant decrease in TGF-β concentrations in the blood sera of treatment groups T1 (35.31 ± 17.33), T2 (43.31 ± 17.42), and T3 (48.67 ± 20.94) pg/mL compared to the PC group (162.09 ± 11.60) pg/mL (p < 0.001). However, only HSE at a dose of 0.99 g/kg BW decreased the PIK3CA gene expression (p = 0.026), and at a dose of 0.66 g/kg BW increased the PTEN expression up to 4.93-fold.</p><p><strong>Conclusion: </strong>HSE is capable of inhibiting the TGF-β/PIK3CA pathway and increasing the PTEN gene expression.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PROGNOSTIC VALUE OF THE DENSITY OF TUMOR-INFILTRATING LYMPHOCYTES AND ITS ASSOCIATION WITH CLINICAL-MORPHOLOGICAL FEATURES OF COLON ADENOCARCINOMAS. 肿瘤浸润淋巴细胞密度的预后价值及其与结肠腺癌临床形态特征的关系。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.045
B Shkurupii, L Zakhartseva

Aim: To study the prognostic value of the density of tumor-infiltrating lymphocytes (TILs) and its association with other clinical-morphological parameters in colon adenocarcinomas (CAC).

Materials and methods: 236 CAC samples were examined. TILs density was estimated as the percentage of tumor stromal area occupied by TILs. By the index of TILs density, the patients were divided into 3 groups: TILs 0-9% (n = 88); TILs 10-39% (n = 106); TILs > 40% (n = 42). Dependent on this index, their overall survival (OS) was analyzed.

Results: Kaplan - Meier curves revealed a significant (p < 0.001) difference in the OS for patients with different TILs infiltration intensities. Multivariate Cox's proportional hazard regression model analysis has confirmed that patients with moderate TILs density (HR 0.57, 95% CI 0.34-0.96, p = 0.035) had better OS rates compared to low TILs density. TILs were associated with the stage (p < 0.001), lymph node metastasis pN (p < 0.001), distant metastasis M (p < 0.001), and the patient's outcome (p < 0.001).

Conclusion: TILs can be considered an additional prognostic tool during regular histological examination and are strongly associated with the most significant clinical-morphological features of CAC.

目的:研究结肠腺癌(CAC)中肿瘤浸润淋巴细胞(TILs)密度的预后价值及其与其他临床形态学参数的关联。TILs密度按TILs占肿瘤基质面积的百分比估算。根据 TILs 密度指数,将患者分为 3 组:TILs 0-9%(88 人);TILs 10-39%(106 人);TILs >40%(42 人)。根据这一指标,对他们的总生存期(OS)进行分析:Kaplan - Meier曲线显示,不同TILs浸润强度的患者的OS差异显著(P < 0.001)。多变量考克斯比例危险回归模型分析证实,与低TILs密度相比,中度TILs密度(HR 0.57,95% CI 0.34-0.96,p = 0.035)患者的OS率更高。TILs与分期(p < 0.001)、淋巴结转移pN(p < 0.001)、远处转移M(p < 0.001)和患者预后(p < 0.001)相关:结论:TILs可作为常规组织学检查的额外预后工具,并与CAC最重要的临床形态特征密切相关。
{"title":"PROGNOSTIC VALUE OF THE DENSITY OF TUMOR-INFILTRATING LYMPHOCYTES AND ITS ASSOCIATION WITH CLINICAL-MORPHOLOGICAL FEATURES OF COLON ADENOCARCINOMAS.","authors":"B Shkurupii, L Zakhartseva","doi":"10.15407/exp-oncology.2024.01.045","DOIUrl":"https://doi.org/10.15407/exp-oncology.2024.01.045","url":null,"abstract":"<p><strong>Aim: </strong>To study the prognostic value of the density of tumor-infiltrating lymphocytes (TILs) and its association with other clinical-morphological parameters in colon adenocarcinomas (CAC).</p><p><strong>Materials and methods: </strong>236 CAC samples were examined. TILs density was estimated as the percentage of tumor stromal area occupied by TILs. By the index of TILs density, the patients were divided into 3 groups: TILs 0-9% (n = 88); TILs 10-39% (n = 106); TILs > 40% (n = 42). Dependent on this index, their overall survival (OS) was analyzed.</p><p><strong>Results: </strong>Kaplan - Meier curves revealed a significant (p < 0.001) difference in the OS for patients with different TILs infiltration intensities. Multivariate Cox's proportional hazard regression model analysis has confirmed that patients with moderate TILs density (HR 0.57, 95% CI 0.34-0.96, p = 0.035) had better OS rates compared to low TILs density. TILs were associated with the stage (p < 0.001), lymph node metastasis pN (p < 0.001), distant metastasis M (p < 0.001), and the patient's outcome (p < 0.001).</p><p><strong>Conclusion: </strong>TILs can be considered an additional prognostic tool during regular histological examination and are strongly associated with the most significant clinical-morphological features of CAC.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1